List of Vosevi drug patents

Vosevi is owned by Gilead Sciences Inc.

Vosevi contains Sofosbuvir; Velpatasvir; Voxilaprevir.

Vosevi has a total of 33 drug patents out of which 0 drug patents have expired.

Vosevi was authorised for market use on 18 July, 2017.

Vosevi is available in tablet;oral dosage forms.

Vosevi can be used as treatment of adult patients with chronic hcv infection who have genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an hcv regimen containing an ns5a inhibitor; treatment of adult patients with chronic hcv infection who have genotype 1a or 3 infection and have previously been treated with an hcv regimen containing sofosbuvir without an ns5a inhibitor, treatment of adult patients with chronic hcv infection who have genotype 1a or 3 infection and have previously been treated with an hcv regimen containing sofosbuvir without an ns5a inhibitor; treatment of adult patients with chronic hcv infection who have genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an hcv regimen containing an ns5a inhibitor.

Drug patent challenges can be filed against Vosevi from July, 2021.

The generics of Vosevi are possible to be released after 01 December, 2037.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8735372 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US8580765 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US9085573 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US8334270 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US9585906 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US7964580 GILEAD SCIENCES INC NA
Mar, 2029

(6 years from now)

US8889159 GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Mar, 2029

(6 years from now)

US8633309 GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2029

(6 years from now)

US9284342 GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2030

(7 years from now)

US8618076 GILEAD SCIENCES INC Nucleoside phosphoramidates
Dec, 2030

(7 years from now)

US8921341 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(9 years from now)

US8575135 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(9 years from now)

US9868745 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(9 years from now)

US8940718 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(9 years from now)

US9296782 GILEAD SCIENCES INC Inhibitors of hepatitis C virus
Jul, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8957046 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US8334270

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US9085573

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US8735372

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US8580765

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US7964580

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2029

(6 years from now)

US8633309

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2029

(6 years from now)

US8889159

(Pediatric)

GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Sep, 2029

(6 years from now)

US9284342

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2031

(8 years from now)

US8618076

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Jun, 2031

(8 years from now)

US8921341

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
May, 2033

(10 years from now)

US8575135

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
May, 2033

(10 years from now)

US8940718

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
May, 2033

(10 years from now)

US11116783 GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jan, 2034

(11 years from now)

US11116783

(Pediatric)

GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jul, 2034

(11 years from now)

US10912814 GILEAD SCIENCES INC Combination formulation of three antiviral compounds
Jun, 2037

(14 years from now)

US11338007 GILEAD SCIENCES INC Combination formulation of three antiviral compounds
Jun, 2037

(14 years from now)

US11338007

(Pediatric)

GILEAD SCIENCES INC Combination formulation of three antiviral compounds
Dec, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 18, 2022

Drugs and Companies using SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR ingredient

NCE-1 date: July, 2021

Market Authorisation Date: 18 July, 2017

Treatment: Treatment of adult patients with chronic hcv infection who have genotype 1a or 3 infection and have previously been treated with an hcv regimen containing sofosbuvir without an ns5a inhibitor; Treatment of adult patients with chronic hcv infection who have genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an hcv regimen containing an ns5a inhibitor

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic